Oct 18, 2016
Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women's cancers, announced today that.
Sep 26, 2016
Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women's cancers, announced today that.
Oct 29, 2015
Nemucore to present on November 4th, 2015 at 9:30 a.m. EDT at The Broad Institute
Oct 19, 2015
Presentation on October 21, 2015 at 11:30 a.m. PDT / 2:30 p.m. EDT
Jun 15, 2015
Nemucore Medical Innovations, Inc., a privately-held biopharmaceutical company dedicated to the development and commercialization of molecularly targeted therapies to treat multidrug resistant cancers, today announced the appointment of Daniel E.
Jun 08, 2015
Election of James B Farinholt Jr. Gives Nemucore's Board a Majority of Independent Directors
Mar 17, 2015
Nemucore Medical Innovations, Inc., a privately-held biopharmaceutical company dedicated to the development and commercialization of molecularly targeted therapies to treat multidrug resistant cancers, today announced the publication of its paper "EGFR...
Oct 02, 2014
Nemucore Medical Innovations, Inc., a privately-held biopharmaceutical company dedicated to the development and commercialization of targeted therapies to treat patients afflicted with multidrug resistant cancers, today announced the publication of its...
Jul 21, 2014
Nemucore Medical Innovations, Inc. (NMI), a privately-held biopharmaceutical company dedicated to the development and commercialization of nanomedicines for the treatment of patients afflicted with multidrug resistant cancers, today announced the...
Jun 24, 2014
Nemucore Medical Innovations, Inc., a privately-held biopharmaceutical company dedicated to the development and commercialization of targeted nanomedicines for the treatment of patients afflicted with multidrug resistant cancers, today announced its...